Phio Pharmaceuticals Corp.
PHIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001533040
In the last 90 days, Phio Pharmaceuticals Corp. insiders filed 5 open-market purchases and 0 sales; 24 institutions reported holding it in 13F filings for Q2 2026, worth $662.6K in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Phio Pharmaceuticals Corp. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 8 | 13 | +5 |
| Shares | 39.1K | 274.8K | +235.7K (+602.3%) |
| Value | $219.7K | $798.3K | +$578.7K (+263.4%) |
New holders (6)
Institutions that held Phio Pharmaceuticals Corp. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Sabby Management, LLC | 156,752 | $449.9K | 1.61% |
| Bridgeway Capital Management, LLC | 23,486 | $67.4K | 0.00% |
| Anson Funds Management LP | 22,571 | $64.8K | 0.02% |
| Bank of Montreal | 10,000 | $38.5K | 0.00% |
| Cetera Investment Advisers | 10,666 | $30.6K | 0.00% |
| Tower Research Capital LLC (TRC) | 1,323 | $3.80K | 0.00% |
Sold out (1)
Institutions that held Phio Pharmaceuticals Corp. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| UBS Group AG | 207 | $1.16K |